Trial Profile
A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Therapeutic Use
- 02 Nov 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 02 Nov 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 16 May 2023 Status changed from recruiting to active, no longer recruiting.